Compare ZDGE & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZDGE | NSRX |
|---|---|---|
| Founded | 2008 | 2019 |
| Country | United States | Israel |
| Employees | 55 | 7 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 38.9M |
| IPO Year | 2016 | N/A |
| Metric | ZDGE | NSRX |
|---|---|---|
| Price | $2.98 | $3.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | ★ 79.1K | 12.2K |
| Earning Date | 06-11-2026 | 03-25-2026 |
| Dividend Yield | ★ 1.96% | N/A |
| EPS Growth | ★ 73.85 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $29,398,000.00 | N/A |
| Revenue This Year | $3.27 | N/A |
| Revenue Next Year | $5.78 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.21 | $1.98 |
| 52 Week High | $4.70 | $9.99 |
| Indicator | ZDGE | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.58 | 57.44 |
| Support Level | $2.88 | $2.83 |
| Resistance Level | $3.16 | $3.60 |
| Average True Range (ATR) | 0.12 | 0.23 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 74.07 | 71.22 |
Zedge Inc builds digital marketplaces and competitive games centered on content that people use for self-expression. Its products include the Zedge App, a freemium digital content marketplace offering mobile wallpapers, video wallpapers, ringtones, and notification sounds, along with pAInt, a generative AI wallpaper and ringtone maker, GuruShots, a skill-based photo challenge game, and Emojipedia, a trusted source for emoji information. The Zedge App is available on Google Play and the App Store. The company operates two segments: Zedge Marketplace and GuruShots, with the majority of revenue generated from the Zedge Marketplace.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.